Sign up
Pharma Capital

Orgenesis teams up with HemoGenyx in second collaboration to push cancer cell replacement product to clinical trials

In part two of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx Pharmaceuticals Plc (LON:HEMO), CEO Vered Caplan of Orgenesis and CEO Vladislav Sandler of HemoGenyx tell Proactive Investors the two biopharmas will work together yet again on HemoGenyx’s Human Postnatal Hemogenic Endothelial Cell (Hu-PHEC) technology.

Hu-PHEC is a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient.

As with the first agreement, Orgenesis will invest at least another $1million in HemoGenyx through a convertible loan, which can be converted into either HemoGenyx or Orgenesis stock.

 

View full ORGS profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.